Vitrafy Life Sciences (VFY) Q2 2026 TU earnings summary

Executive summary

• Achieved a 12-month exclusive commercial agreement with IMV Technologies, marking a major milestone in animal reproduction cryopreservation and providing a clear path to scale in the market.

• Established a U.S. office and operational base in Southern California/Irvine, supporting business development, manufacturing, and market entry.

• Strengthened the board with appointments of Dr. Leigh Farrell as Chair and Dr. Jeannie (Jeannette) Joughin as Non-Executive Director, enhancing expertise in biotech and biopharma.

• Progressed U.S. Army Phase II platelet cryopreservation program, with initial data expected in Q3 FY2026.

• Delivered and launched the first Guardion device in North America, supporting commercial launch and customer onboarding.

Financial highlights

• Ended Q2 FY2026 with cash and short-term assets of A$22.8m, providing a strong balance sheet and funding runway well into calendar year 2027.

• Net cash outflow for the quarter was A$3.0m, with average monthly cash burn of ~$1.65m.

• Receipts included A$1.0m from FY25 R&D refund, A$0.8m from Industry Growth Program grant, and ~A$2.0m from aquaculture, interest, and government grants.

• Industry Growth Program grant funding balance of ~A$1.6m due over the next 12 months.

• Payments to directors and related parties totaled A$218,000 for the quarter.

Outlook and guidance

• Focused on executing the IMV agreement, commercializing human health pipeline opportunities, and expanding in North America in the next 6 months.

• Plans to secure U.S. medical device registration (Class II) in 1H FY2027 to expand the addressable market.

• Ongoing investment in Guardion unit production, manufacturing expansion, and commercial deployment.

• Activities under the IMV agreement to commence in February 2026.

• Average quarterly cash costs expected to rise 10–15% in the current half due to regulatory and commercial expansion.